Bisphosphonates and osteonecrosis of the jaws

Yıl 2013, Cilt: 30 Sayı: 1, 35 - 8, 11.03.2013

Arzu Zeynep Yıldırım Biçer

Öz

Bisphosphonates are widely used for treatment of many bone metabolism related disease. Intravenous administration of high doses of bisphosphonates for the management of benign conditions occasionally lead to development of osteonecrosis of the jaws. In many cases lesions appear spontaneously or following an infection or a tooth extraction. Dentists should be cautious in the treatment of patients using bisphosphonates.

Anahtar Kelimeler

Bisphosphonate, Jaw, Osteonecrosis

Bifosfonatlar ve çenelerde görülen osteonekroz

Öz

Bifosfonatlar günümüzde kemik metabolizması ile ilgili pek çok hastalığın tedavisinde yaygın olarak kullanılmaktadır. Bifosfonatların yüksek dozda intravenöz uygulamaları nedeni ile ilaca bağlı bir yan etki olarak çenelerde osteonekroz oluşabilmektedir. Lezyonlar kendiliğinden oluşabildiği gibi bir enfeksiyon ve diş çekimi genellikle olayı hızlandırmaktadır. Bu nedenle diş hekimleri bifosfonat kullanan hastaların tedavisinde dikkatli olmalıdırlar.

Anahtar Kelimeler

Bifosfonat, Çene, Osteonekroz

Kaynakça

• Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90:1897-99.
• Ergün S, Güneri P, Koca H. Çene kemiklerinin yeni tehlikesi: bifosfonatlar. Cumhuriyet Üniversitesi Diş Hekimliği Fakültesi Derg 2008;11(2):140-5.
• Bock O, Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice Clin Interv Aging 2008;3:279-97.
• MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Inter Med 2008;148:197-213.
• Nase JB, Suzuki JB. Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 2006;137:1115-9.
• Reilly MM. Osteonecrosis of the jaw in a patient receiving bisphosphonate therapy. Oncol Nurs Forum 2007;34:301-5.
• Mashiba T, Mori S, Burr DB, Komatsubara S, Cao Y, Manabe T, et al. The effects of suppressed bone remodelling by bisphosponates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005;23:36-42.
• Akarslan ZZ, Kahraman SA. Kemik metastazı yapmış prostat kanseri tedavisinde kullanılan bifosfonata bağlı olarak çene kemiklerinde gelişen osteonekroz: vaka raporu ve literatür derlemesi. Atatürk Üniv Diş Hek Fak Derg 2008;18:105-10.
• Fleish H. Bisphosphonates: mechanism of action. Endocr Rev 1998;19:80-100.
• Sarıdoğan M. Postmenopozal osteoporoz tedavisi: bifosfonatlar. Akad Geriatri 2010;183-8.
• Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.
• Lin JH, Russell G, Gertz B. Pharmacokinetics of alendronate: an overview. Int J Clin Pract Suppl 1999;101:18-26.
• Markiewicz MR, Margarone JE 3rd, Campbell JH, Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc 2005;136:1669-74.
• Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, et al. Zoledronic acid-related antiangiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005;25:144-51.
• Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphophonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.
• Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136:1658-68.
• Weinstein RS. True strength. J Bone Miner Res 2000;15:621-5.
• Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457-63.
• Reid IR. Emerging issues with bsphosphonates.Rheum Dis Clin North Am 2006;32:691-702.
• Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonates-induced exposed bone (osteonecrosis / osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
• Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 2002;32:94-124.
• Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, et al. Practical guidelines for the prevention, diagnosis and treatment of osteonecrosis of the jaw in patients with cancer. J Clin Pract 2006;2:7-14.
• Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates:a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
• Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bisphossy jaw): is this phossy jaw of the 21st century? J Oral and Maxillofac Surg 2005;63:682-9.
• Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emergeing oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
• Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7.
• Greenberg MS. Intravenous bisphosphonates and osteonecrosis. Oral Surg Med Oral Pathol 2004;98:259-60.
• Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet- derived growth factors. J Am Dent Assoc 2007;138:971-7.
• Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004;62:489-96.
• Jones LC, Mont MA, Le TB, Petri M, Hungerford DS, Wang P, et al. Procoagulants and osteonecrosis. J Rheumatol 2003;30:783-91.